10-Q: Mineralys Reports Strong Lorundrostat Trial Results

Mineralys Therapeutics announced positive pivotal and Phase 2 clinical trial results for lorundrostat in hypertension and chronic kidney disease, while securing significant capital.

Summary

• Mineralys Therapeutics, a clinical-stage biopharmaceutical company, is developing lorundrostat, an orally administered aldosterone synthase inhibitor, for cardiorenal conditions.
• The company reported positive, statistically significant, and clinically meaningful results from its pivotal Phase 3 Launch-HTN and Phase 2 Advance-HTN trials for uncontrolled or resistant hypertension.
• Launch-HTN showed a -9.1 mmHg placebo-adjusted systolic BP reduction at Week 6 (p<0.0001) for the 50 mg dose.
• Advance-HTN demonstrated a -7.9 mmHg placebo-adjusted 24-hour ambulatory systolic BP reduction at Week 12 (p=0.001) for the 50 to 100 mg dose.
• Positive topline data from the Phase 2 Explore-CKD trial for hypertension with comorbid chronic kidney disease showed a -7.5 mmHg placebo-adjusted systolic BP reduction (p=0.0024) and a -25.60% placebo-adjusted urine albumin-to-creatinine ratio (UACR) reduction (p=0.0015).
• The company initiated the Phase 2 Explore-OSA trial for obstructive sleep apnea and hypertension in Q1 2025, with topline results expected in H1 2026.
• As of June 30, 2025, cash, cash equivalents, and investments totaled $324.9 million.
• Net loss for the six months ended June 30, 2025, increased to $85.5 million from $72.5 million in the prior year period.
• Net cash used in operating activities for the six months ended June 30, 2025, was $75.7 million, up from $49.3 million in the prior year period.
• The company successfully completed a public offering in March 2025, raising approximately $188.7 million in net proceeds.
• An At-The-Market (ATM) equity offering generated $9.5 million in net proceeds from April to June 30, 2025, with an additional $7.9 million through August 12, 2025.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical trial results for lorundrostat across multiple indications, which is a significant de-risking event for a clinical-stage biopharmaceutical company. The successful capital raises provide a solid financial runway for at least 12 months, supporting continued development and pre-commercialization activities. While net losses and cash burn increased, this is expected for a company at this stage of development. The clear path to an NDA meeting in Q4 2025 further enhances the positive outlook.

Positives

• Lorundrostat's pivotal Phase 3 Launch-HTN and Phase 2 Advance-HTN trials successfully achieved statistical significance and clinically meaningful primary efficacy endpoints for uncontrolled or resistant hypertension, demonstrating a favorable safety and tolerability profile.
• The Phase 2 Explore-CKD trial showed highly statistically significant and clinically meaningful reductions in both systolic blood pressure (-7.5 mmHg placebo-adjusted, p=0.0024) and urine albumin-to-creatinine ratio (-25.60% placebo-adjusted, p=0.0015) in hypertensive participants with chronic kidney disease.
• The company's cash, cash equivalents, and investments of $324.9 million as of June 30, 2025, are believed to be sufficient to fund operations for at least twelve months from the filing date.
• Successful capital raises, including a public offering netting $188.7 million in March 2025 and $17.4 million from ATM sales through August 12, 2025, significantly bolstered liquidity.
• The FDA cleared the investigational new drug application for the Explore-OSA trial in January 2025, expanding lorundrostat's potential indications.

Negatives

• Net loss increased to $85.5 million for the six months ended June 30, 2025, compared to $72.5 million for the same period in 2024.
• Net cash used in operating activities increased to $75.7 million for the six months ended June 30, 2025, from $49.3 million in the prior year, indicating a higher cash burn rate.
• The accumulated deficit grew to $388.0 million as of June 30, 2025, reflecting continued operating losses since inception.
• Research and development expenses increased by $6.1 million for the six months ended June 30, 2025, driven by compensation and clinical costs.
• General and administrative expenses increased by $4.5 million for the six months ended June 30, 2025, primarily due to higher compensation and professional fees.

Risks

• The company has incurred significant operating losses and negative cash flows since inception and expects to continue incurring substantial losses in the foreseeable future.
• Additional funding will be required in the future to continue planned research and development and other activities, with no committed external source of funds.
• The ability to raise additional funds may be adversely impacted by worsening global economic conditions, high interest rates, elevated inflation, geopolitical conflicts, and supply chain disruptions.
• Failure to raise capital when needed or on favorable terms could force delays, limitations, reductions, or termination of product development or future commercialization efforts.
• Future equity offerings or convertible debt securities could dilute the ownership interest of existing stockholders.
• Debt financing, if available, may include covenants limiting the company's ability to take specific actions.
• Inflation could adversely affect the business by increasing costs for labor, research and development contracts, and other operational expenses.
• Changes in trade policy and tariffs could make procuring materials for active pharmaceutical ingredients more difficult or costly.
• The timing, duration, and completion costs of current or future clinical trials and preclinical studies are inherently unpredictable and can differ materially from expectations.
• The company may be required to relinquish valuable rights to future revenue streams, product candidates, or intellectual property if additional funds are raised through collaborations or licensing arrangements.

Future Outlook

The company plans to conduct a pre-new drug application (NDA) meeting with the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2025 for lorundrostat for the treatment of uncontrolled and resistant hypertension. Enrollment is ongoing for the Phase 2 Explore-OSA trial, with topline results anticipated in the first half of 2026. The company expects to continue incurring substantial losses and negative cash flows as it advances clinical development, seeks regulatory approvals, and expands commercialization capabilities. Future operations are expected to be financed through equity offerings, debt financings, or strategic collaborations, as the company does not anticipate generating revenue from product sales until lorundrostat receives regulatory approval.

Management Comments

• "We believe clinical safety findings in the two pivotal trials, including adrenocorticotropic hormone-stimulated and serum cortisol, change in serum potassium, serum sodium, and estimated glomerular filtration rate (eGFR), as well as incidence of hypotension, support a favorable benefit-risk profile."
• "We also believe the Launch-HTN and Advance-HTN results demonstrate the opportunity for lorundrostat in third-line or later treatment of patients with hypertension."
• "We also believe, based on available clinical data, that our product candidate holds promise to be an innovative solution for the rapidly growing unmet need in multiple cardiorenal metabolic disorders."
• "Based on our current operating plan, we believe that our cash, cash equivalents, and investments as of June 30, 2025 will be sufficient to allow us to fund our operations for at least twelve months."

Industry Context

The company operates in the cardiorenal biopharmaceutical sector, targeting diseases driven by dysregulated aldosterone. Hypertension affects approximately 120 million patients in the United States, with over half failing to achieve blood pressure goals with existing medications. Dysregulated aldosterone is a key factor in about 30% of hypertensive patients, indicating a significant unmet medical need that lorundrostat aims to address. The observed reduction in eGFR with lorundrostat is consistent with effects seen with other established renin-angiotensin-aldosterone pathway inhibitors like ACE inhibitors, ARBs, and mineralocorticoid receptor antagonists, suggesting a similar physiological impact on kidney function.

Comparison to Industry Standards

• The observed reduction in eGFR with lorundrostat is consistent with the effects seen with other renin-angiotensin-aldosterone pathway inhibitors, including ACE inhibitors, ARBs, and mineralocorticoid receptor antagonists, which also cause a modest decrease in eGFR due to reduced over-perfusion of glomeruli.
• The company highlights that over 30 million treated hypertension patients do not achieve their blood pressure goal, with approximately 20 million having systolic BP levels greater than 140 mmHg, indicating a substantial market for new, effective treatments like lorundrostat.
• The clinical trial design for Launch-HTN, utilizing automated office blood pressure measurement and allowing participants to stay on existing medications, reflects a real-world setting for clinicians, which is a valuable approach in hypertension trials.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings, and no material legal proceedings are currently pending or threatened.

Stakeholder Impact

• **Shareholders**: Potential for increased share value due to positive clinical trial results and progress towards regulatory approval, but also face dilution from recent and potential future equity offerings.
• **Patients**: Lorundrostat offers a promising new treatment option for a large population suffering from uncontrolled/resistant hypertension, chronic kidney disease, and potentially obstructive sleep apnea.
• **Employees**: Increased headcount and stock-based compensation indicate growth and investment in human capital.
• **Investment Professionals**: The positive clinical data and clear regulatory pathway provide actionable insights for investment decisions.
• **Regulatory Authorities**: The company's progress towards an NDA filing for lorundrostat will be of interest to regulatory bodies like the FDA.

Next Steps

• Conduct a pre-new drug application (NDA) meeting with the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2025 for lorundrostat for the treatment of uncontrolled and resistant hypertension.
• Continue enrollment for the Phase 2 Explore-OSA trial.
• Anticipate reporting topline results from the Explore-OSA trial in the first half of 2026.
• Continue to fund operations through equity offerings, debt financings, and potential strategic collaborations or licensing arrangements.
• Advance commercial readiness activities for lorundrostat, if approved.

Key Dates

Recommendation

The filing demonstrates significant de-risking for Mineralys Therapeutics with highly positive and statistically significant clinical trial results for lorundrostat in major indications like hypertension and CKD. The successful completion of pivotal trials and the clear plan for an NDA meeting in Q4 2025 indicate a strong progression towards commercialization. Furthermore, the company has substantially strengthened its financial position through recent capital raises, providing a runway for at least 12 months, which mitigates immediate liquidity concerns. While the company remains pre-revenue and cash-flow negative, the compelling clinical data and strategic funding position it favorably for future growth and potential market entry, making it an attractive investment for long-term growth.

Keywords

Lorundrostat, Hypertension, Aldosterone Synthase Inhibitor, Cardiorenal, Chronic Kidney Disease, Obstructive Sleep Apnea, Clinical Trials, Biopharmaceutical, Drug Development, SEC Filing, 10-Q, Clinical-stage, Public Offering, ATM Offering, Private Placement